R-tech Ueno Completes Phase II For Ocuseva
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based R-tech Ueno announced June 3 completion of a Phase II study for Ocuseva (UF-021) eye drops for retinitis pigmentosa, a rare disease expected to affect one in 5,000 people